See more : RATIONAL Aktiengesellschaft (RAA.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Impel Pharmaceuticals Inc. (IMPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Impel Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- PT Bank JTrust Indonesia Tbk (BCIC.JK) Income Statement Analysis – Financial Results
- Infrastrutture Wireless Italiane S.p.A. (IFSUF) Income Statement Analysis – Financial Results
- Electricité et Eaux de Madagascar Société Anonyme (EEM.PA) Income Statement Analysis – Financial Results
- First Western Financial, Inc. (MYFW) Income Statement Analysis – Financial Results
- Pact Group Holdings Ltd (PGH.AX) Income Statement Analysis – Financial Results
Impel Pharmaceuticals Inc. (IMPL)
About Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 12.65M | 668.00K | 0.00 | 0.00 |
| Cost of Revenue | 6.50M | 691.00K | 0.00 | 0.00 |
| Gross Profit | 6.16M | -23.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 48.66% | -3.44% | 0.00% | 0.00% |
| Research & Development | 11.46M | 20.56M | 27.29M | 28.81M |
| General & Administrative | 77.89M | 50.90M | 18.05M | 12.75M |
| Selling & Marketing | 7.60M | 12.60M | 0.00 | 0.00 |
| SG&A | 77.89M | 50.90M | 18.05M | 12.75M |
| Other Expenses | -9.29M | -5.05M | -408.00K | -680.00K |
| Operating Expenses | 89.34M | 71.46M | 45.33M | 41.57M |
| Cost & Expenses | 95.84M | 72.15M | 45.33M | 41.57M |
| Interest Income | 10.58M | 2.25M | 0.00 | 417.00K |
| Interest Expense | 13.84M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.20M | 1.09M | 1.08M | 722.00K |
| EBITDA | -83.18M | -70.40M | -44.26M | -40.84M |
| EBITDA Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Operating Income | -83.18M | -71.49M | -45.33M | -41.57M |
| Operating Income Ratio | -657.48% | -10,701.50% | 0.00% | 0.00% |
| Total Other Income/Expenses | -23.13M | -5.05M | -463.00K | -263.00K |
| Income Before Tax | -106.31M | -76.53M | -45.80M | -41.83M |
| Income Before Tax Ratio | -840.28% | -11,457.19% | 0.00% | 0.00% |
| Income Tax Expense | 23.13M | 2.00K | 1.00K | 30.00K |
| Net Income | -129.44M | -76.54M | -45.80M | -41.86M |
| Net Income Ratio | -1,023.08% | -11,457.49% | 0.00% | 0.00% |
| EPS | -5.52 | -5.24 | -3.49 | -3.19 |
| EPS Diluted | -5.52 | -5.24 | -3.49 | -3.19 |
| Weighted Avg Shares Out | 23.45M | 14.60M | 13.14M | 13.14M |
| Weighted Avg Shares Out (Dil) | 23.45M | 14.60M | 13.14M | 13.14M |
Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale
Why Is Impel Pharmaceuticals (IMPL) Stock Up 32% Today?
Why Is Impel Pharmaceuticals (IMPL) Stock Down 35% Today?
Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society
Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023
Impel Pharmaceuticals Inc. (IMPL) Q4 2022 Earnings Call Transcript
Impel Pharmaceuticals Inc. (IMPL) Reports Q4 Loss, Tops Revenue Estimates
Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023
Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March
Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports